Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease

Balk, Ethan M; Lau, Joseph; Goudas, Leonidas C.; Jordan, H; Kupelnick, Bruce; Kim, Linda U.; Karas, Richard H.

doi:10.7326/0003-4819-139-8-200310210-00011

Cited by 186 publications

(122 citation statements)

References 109 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…In 1998, investigators working in the Cholesterol and Recurrent Events (CARE) trial reported that the clinical benefit of statins in terms of event reduction was greater among those with increased CRP, and that statin therapy reduces CRP concentrations in a largely LDL-independent manner (33,34 ). These observations were subsequently confirmed for all statins (35)(36)(37)(38)(39), although more potent agents such as rosuvastatin appear to result in even greater LDL and CRP reductions. Thus, by 1999, evidence was rapidly accruing not only that CRP might represent a novel biomarker of vascular risk, but that CRP evaluation might also merit consideration as a method to monitor pharmacologic interventions used to prevent and treat cardiovascular disease.…”

Section: C-reactive Protein (Crp)supporting

confidence: 51%

C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease

2009

View full text Add to dashboard Cite

Section: C-reactive Protein (Crp)supporting

confidence: 51%

C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease

2009

View full text Add to dashboard Cite

“…Moreover, statins, which inhibit the major rate limiting step of the mevalonate pathway, namely the conversion of HMGCoA into mevalonate, have consistently been shown to lower CRP. 27 Meanwhile, a recent study suggested that the contribution of the e4 allele towards lowering CRP levels is independent and may be by a different mechanism than how statins affect inflammation. 19 However, implication of lipoprotein pathway of the cholesterol transport remained plausible since Schwalbe et al 28 reported that CRP may be complexed with lipoprotein by a direct interaction with the apolipoprotein E molecule, suggesting a direct effect of the APOE e4 allele on hs-CRP concentration.…”

Section: Discussionmentioning

confidence: 99%

Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles

et al. 2007

View full text Add to dashboard Cite

We aimed at estimating additive genetic heritability, household component effect and the influence of common alleles of the apolipoprotein E gene (APOE) on serum high-sensitivity C-reactive protein (hs-CRP) concentrations and the subsequent changes over 5 years. A sub-sample of 320 nuclear families was randomly selected from the Stanislas Family Study. Serum hs-CRP concentration was measured by immunonephelometry at entrance and after 5 years. APOE alleles were determined by restriction fragment length polymorphism. After adjustment for covariates, the number of the e4 allele was negatively associated with serum concentration of hs-CRP in the whole sample, at entrance and 5 years later, without significant interaction with sex by generation groups (P ¼ 0.003 and P ¼ 0.0003, respectively). However, no significant association was found between e4 allele and 5-year changes in hs-CRP concentration. Using a variance component analysis, no significant genetic influence was shown in family aggregation of both hs-CRP measurements and 5-year changes; the household common component was between 6.5 and 12.8%. In addition, after adjustment for APOE gene polymorphisms, degrees of resemblance were almost unchanged. In the Stanislas Family Study, e4 allele of the APOE gene was associated with lower hs-CRP concentration, but not with 5-year changes. However, variance component analysis did not evidence a significant polygenic effect.

show abstract

“…Other drugs with a Fiblowering effect are angiotensin converting enzyme inhibitors (ACEI) [65], angiotensin receptor blockers (ARB) [66], -blockers [66,67] and ticlopidine [68]. Despite significant reductions sporadically reported in some pravastatin studies [69][70][71], Fib-lowering action of statins is disputable [72]. Studies on PAD patients showed that the use of vasodilators [73], rheological [74] and thrombolytic [75,76] agents leads to reduced Fib levels, usually accompanied by clinical improvement.…”

Section: Fib and Cvd Pathophysiologymentioning

confidence: 99%

Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!

Lioudaki¹,

Ganotakis²

2012

TOCCHEMJ

View full text Add to dashboard Cite

Cardiovascular disease (CVD) remains a leading cause of global morbidity and mortality despite identification of major cardiovascular (CV) risk factors and risk reduction via appropriate interventions. During the last years several markers have been studied as potential predictors of CV events. Hemostatic and thrombotic factors such as fibrinogen, homocysteine, factor VII, von Willebrand, tissue plasminogen activator, plasminogen activator inhibitor -1, D-dimer and lipoprotein ( ) have been found to be closely related to CVD. Many epidemiological studies have indicated that raised levels of these factors are associated with higher incidence of CVD, while some others have yielded conflicting results. As a consequence, it remains obscure whether they contribute to prediction of future CV events on top of conventional risk factors. Although data suggest that most of them are somehow implicated in CVD pathophysiology, it is not clearly defined yet whether treatment of abnormal levels leads to CV risk reduction. As a result measurement and treatment of these factors are justified only in exceptional cases. Further investigation is required in order to conclude whether and which of these factors may claim a position in everyday clinical practice.

show abstract

Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease

Cited by 186 publications

References 109 publications

C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease

C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease

Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles

Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!

Contact Info

Product

Resources

About